PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.
Langerhans cells (LCs) are known as "sentinels" of the immune system that function as professional antigen-presenting cells (APCs) after migration to draining lymph node. LCs are proposed to have a role in tolerance and the resolution of cutaneous immune responses. The Programmed Death-1 (PD-1) receptor and its ligands, PD-L1 and PD-L2, are a co-inhibitory pathway that contributes to the negative regulation of T-lymphocyte activation and peripheral tolerance. Surprisingly, we found PD-1 to be expressed on immature LCs (iLCs) in situ. PD-1 engagement on iLCs reduced IL-6 and macrophage inflammatory protein (MIP)-1alpha cytokine production in response to TLR2 signals but had no effect on LC maturation. PD-L1 and PD-L2 were expressed at very low levels on iLCs. Maturation of LCs upon migration from epidermis led to loss of PD-l expression and gain of high expression of PD-L1 and PD-L2 as well as co-stimulatory molecules. Blockade of PD-L1 and/or PD-L2 on migratory LCs (mLCs) and DDCs enhanced T-cell activation, as has been reported for other APCs. Thus the PD-1 pathway is active in iLCs and inhibits iLC activities, but expression of receptor and ligands reverses upon maturation and PD-L1 and PD-L2 on mLC function to inhibit T-cell responses.
Peña-Cruz
Victor
V
Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
McDonough
Sean M
SM
Diaz-Griffero
Felipe
F
Crum
Christopher P
CP
Carrasco
Ruben D
RD
Freeman
Gordon J
GJ
D017951:Antigen Presentation / Q000276:immunology*; D015703:Antigens, CD / Q000378:metabolism*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D060890:B7-H1 Antigen; D002450:Cell Communication / Q000276:immunology; D002454:Cell Differentiation / Q000276:immunology; D002465:Cell Movement / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D016130:Immunophenotyping; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D019169:Jurkat Cells; D007801:Langerhans Cells / Q000276:immunology / Q000378:metabolism*; D008024:Ligands; D008213:Lymphocyte Activation / Q000276:immunology; D008562:Membrane Glycoproteins / Q000378:metabolism; D061027:Programmed Cell Death 1 Ligand 2 Protein; D061026:Programmed Cell Death 1 Receptor; D015398:Signal Transduction / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000378:metabolism; D015854:Up-Regulation / Q000276:immunology; D000097802:CD83 Antigen
D015703:Antigens, CD; D051017:Apoptosis Regulatory Proteins; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D060890:B7-H1 Antigen; D016207:Cytokines; D007136:Immunoglobulins; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D008562:Membrane Glycoproteins; D061027:Programmed Cell Death 1 Ligand 2 Protein; D061026:Programmed Cell Death 1 Receptor; D051195:Toll-Like Receptor 2; D000097802:CD83 Antigen; C423236:CD274 protein, human; C497964:CD86 protein, human; C105992:PDCD1 protein, human; C556977:PDCD1LG2 protein, human; C495342:TLR2 protein, human
J Invest Dermatol. 2008 Aug;128(8):1950-5
18337832
Int Immunol. 2007 Jul;19(7):813-24
17606980
Nature. 1998 Mar 19;392(6673):245-52
9521319
J Exp Med. 2006 Apr 17;203(4):883-95
16606670
J Virol. 2002 Dec;76(24):12866-76
12438612
Allergy. 2009 Nov;64(11):1580-7
19392987
J Immunol. 2009 Oct 15;183(8):5085-93
19801524
Nat Rev Immunol. 2008 Jun;8(6):467-77
18500231
J Exp Med. 2003 Jul 7;198(1):63-9
12847137
J Immunol. 2004 Jul 15;173(2):945-54
15240681
Nat Immunol. 2001 Mar;2(3):261-8
11224527
Cytokine Growth Factor Rev. 2008 Feb;19(1):41-52
18258476
FEBS Lett. 2004 Sep 10;574(1-3):37-41
15358536
Nature. 2006 Feb 9;439(7077):682-7
16382236
J Immunol. 2000 Apr 15;164(8):4105-10
10754304
Annu Rev Immunol. 2003;21:685-711
12615891
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11823-8
16087865
J Immunol. 2003 Feb 1;170(3):1257-66
12538684
Nat Med. 2006 Dec;12(12):1372-9
17143276
Eur J Immunol. 2003 Oct;33(10):2706-16
14515254
J Immunol. 2002 Nov 15;169(10):5538-45
12421930
J Exp Med. 2000 Oct 2;192(7):1027-34
11015443
J Exp Med. 2006 Oct 2;203(10):2223-7
17000870
FASEB J. 2003 Oct;17(13):1892-4
12923066
J Immunol Methods. 2001 Sep 1;255(1-2):83-91
11470289
J Exp Med. 2003 Jul 7;198(1):71-8
12847138
J Leukoc Biol. 2008 May;83(5):1118-27
18252867
Am J Surg Pathol. 2006 Jul;30(7):802-10
16819321
Immunity. 2007 Dec;27(6):927-40
18082433
J Exp Med. 2003 Jul 7;198(1):39-50
12847136
Nature. 2006 Sep 21;443(7109):350-4
16921384
Eur J Immunol. 2008 Sep;38(9):2369-76
18792030
Annu Rev Immunol. 2005;23:515-48
15771580
J Leukoc Biol. 1999 Jul;66(1):33-9
10410987
Blood. 2009 Jun 4;113(23):5811-8
19339692
Immunity. 2005 Dec;23(6):611-20
16356859
J Biol Chem. 2006 Apr 14;281(15):10489-95
16439361
J Immunol. 2000 Oct 15;165(8):4397-404
11035077
Nat Rev Immunol. 2008 Dec;8(12):935-47
19029989
Nat Immunol. 2009 Nov;10(11):1185-92
19783989
Infect Immun. 2009 May;77(5):1881-7
19273564
J Invest Dermatol. 2005 Jul;125(1):116-25
15982311
Immunol Lett. 2004 Jul 15;94(3):215-22
15275969
J Biol Chem. 2007 Jun 1;282(22):16042-53
17392283
Clin Vaccine Immunol. 2008 Apr;15(4):630-7
18287580
J Exp Med. 2001 Sep 17;194(6):769-79
11560993
J Exp Med. 2002 Dec 16;196(12):1627-38
12486105
Immunol Lett. 2002 Oct 21;84(1):57-62
12161284
J Immunol. 2006 Mar 1;176(5):2808-16
16493037